BoomRx, a pharmaceutical technology platform that simplifies prescription sourcing and fulfillment by providing healthcare professionals (HCPs) with access to weight management therapies, has now made both oral semaglutide and tirzepatide options available via its platform.¹ The options will be using advanced nanoemulsion delivery, for use by medical clinics, telemedicine providers, wellness facilities, and med spas.

What is nanoemulsion technology and how does it improve drug absorption?

According to a report published in Scientifica,² “Nanoemulsions, also known as nanometric-sized emulsions, are fine water-in-oil (w/o) and oil-in-water (o/w) dispersions of two immiscible fluids, as opposed to the milky-white hue concomitant with coarse dispersion. These 20–200 nm droplets are stabilized by adding the appropriate amphiphilic emulsifiers or emulsifiers.”

Why does delivery format matter for semaglutide and tirzepatide?

By utilizing nanoemulsion technology, the formulations convert each dose into ultra-small particles that promote uniform distribution and enhanced bioavailability. The needle-free delivery format supports greater treatment flexibility and reliability as weight-management care expands into sustained, scalable models.

"Semaglutide and tirzepatide have become foundational therapies in weight management, and how they're delivered matters," noted Kurt Lunkwitz, BoomRx’s founder and president in a company news release.¹ "On the clinical side, nanoemulsion delivery provides an injection-free option designed for consistency and predictability—eliminating the performance peaks and troughs that come with using these products. On the distribution side, BoomRx ensures healthcare providers nationwide can quickly and easily fulfill prescriptions for these therapies through one streamlined portal."

As the industry knows, demand for medical weight loss therapies is on the rise. Keeping that in mind, HCPs are prioritizing delivery formats that help address patient adherence and dosing challenges. By condensing particle sizes at the molecular level, the active ingredients are not only more evenly distributed, but more readily absorbed.

What’s new with oral semaglutide approval and market availability?

Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight and help with weight maintenance. It officially hit the market earlier this month, and has since been added to both the Amazon Pharmacy and GoodRx networks.

This new version of Wegovy in pill form represents the first ever oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy that’s been approved for weight management. It also now marks the third formulation of Wegovy, expanding its available options.

The GLP-1 agonist was initially approved in June 2021 for chronic weight management in adults with obesity or overweight who have at least one related condition, such as hypertension, type 2 diabetes, or high cholesterol, alongside diet and exercise. In 2024, its label was further expanded to include adults with cardiovascular disease.

Tirzepatide—often known under the brand names Mounjaro and Zepbound—is yet to be approved orally, but is available as an injection.

How does BoomRx’s platform simplify prescribing and fulfillment for providers?

As for BoomRx's platform, HCPs are reportedly¹ able to:

• Compare formulations using one centralized dashboard
• Simplify ordering and fulfillment via one secure login
• Scale weight-management programs across both in-office and virtual care environments

"Our role is to remove friction from how healthcare providers source and manage therapies," Lunkwitz added. "As delivery options evolve, BoomRx ensures access stays simple, efficient, and built for growth."

References

1. BoomRx Introduces Oral Semaglutide and Tirzepatide for Healthcare Providers Nationwide. GlobeNewswire. January 14, 2026. Accessed January 19, 2026. https://www.prnewswire.com/news-releases/boomrx-introduces-oral-semaglutide-and-tirzepatide-for-healthcare-providers-nationwide-302660680.html

2. Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, Saharan R, Kumar S, Geeta, Sehrawat R. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs. Scientifica (Cairo). 2023 Oct 28;2023:6640103. doi: 10.1155/2023/6640103. PMID: 37928749; PMCID: PMC10625491.